Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
Zacks News
Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug
by Zacks Equity Research
Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).
Allergan (AGN) Presents Mixed Depression Data on Botox
by Zacks Equity Research
Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).
Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) recently announced plans to reduce its workforce by approximately 20%.
Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst
by Zacks Equity Research
Celgene Corporation (CELG) recently received a Paragraph IV Notice Letter advising that Teva Pharmaceutical Industries Limited (TEVA) submitted an ANDA to the FDA seeking an approval to manufacture and market a generic version of Pomalyst.
5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now
by Zacks Equity Research
Lily carries a Zacks Rank #2 (Buy).
Teva's Austedo Gets FDA Nod for Huntington Disease Treatment
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that the FDA has approved its investigational drug, Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington disease (HD).
Allergan Acne Candidate Meets Endpoints in Phase III Studies
by Zacks Equity Research
Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline
Teva Pharma Denies Rumors of Global Workforce Reduction
by Zacks Equity Research
According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.
Allergan's Restasis Now Available in Multidose Bottle in U.S.
by Zacks Equity Research
Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
by Zacks Equity Research
Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.
Nektar's Pain Drug Positive in Phase III Study; Shares Gain
by Zacks Equity Research
Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
by Zacks Equity Research
London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.
Teva Launches Authorized Generic of Allergan's Minastrin
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.
What's Driving Lilly's (LLY) Shares after 2016 Decline?
by Zacks Equity Research
After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.
Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.
Teva (TEVA) Tops Q4 Earnings & Sales Estimates; Shares Up
by Zacks Equity Research
Teva???s fourth quarter earnings (including equity compensation expenses), came in at $1.34 per share, beating consensus estimates of $1.32.
Bartosiak: Trading Teva Pharmaceutical's (TEVA) Earnings with Options
by David Bartosiak
Join David Bartosiak to see his thoughts on Teva Pharma (TEVA) ahead of their earnings announcement, and he'll give us real time insight on how to play the options market.
Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat
by Kinjel Shah
Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.
Teva (TEVA) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.
Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.
Allergan (AGN) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.
Momenta Says District of Delaware Invalidates Teva's MS Drug
by Zacks Equity Research
Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .
Mylan (MYL) Gets Favorable Verdict for Copaxone in the US
by Zacks Equity Research
Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the company pertaining to claims related to Teva Pharmaceutical's (TEVA) Copaxone 40mg/mL.
Allergan (AGN) Avycaz Label to Include New Phase III Data
by Zacks Equity Research
Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.